Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label Phase III Study of First-line Treatment With Erlotinib Intercalated With Gemcitabine/ Cisplatin or Carboplatin Therapy Versus Erlotinib in Stage IIIB/IV NSCLC Patients With EGFR Mutation
Conditions
Interventions
gemcitabine; cisplatin or carboplatin; erlotinib
erlotinib
Locations
1
China
Xinjiang medical university
Ürümqi, Xinjiang, China
Start Date
December 1, 2013
Primary Completion Date
June 1, 2015
Completion Date
June 1, 2015
Last Updated
December 5, 2013
NCT06305754
NCT07190248
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Xinjiang Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions